Ligand Presents First-in-Human Phase I Data on Lead SARM Molecule LGD-4033 at the International Congress of Endocrinology
Ligand Announces Approval for Revolade(R) in Europe
Ligand to Present at the Cowen & Company 30th Annual Healthcare Conference on March 11
Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results
Ligand to Report Fourth Quarter Results on February 9th
Ligand Completes Acquisition of Metabasis
Ligand Earns $1 Million in Milestone Payment from Merck & Co., Inc.
Ligand Completes Neurogen Acquisition
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
Ligand and Neurogen Amend Merger Agreement
Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
Ligand Pharmaceuticals Announces Third Quarter Results
Ligand's JAK3 Research Collaboration Extended by Pfizer
